Test for abnormal niacin response syndrome in schizophrenia: reclaiming the oral route

Authors

  • Francisco Carena Médico, Universidad Nacional de Rosario, Argentina. Magíster en Psicoinmunoneuroendocrinología, Universidad Favaloro, Argentina. Médico Director Hospital S.A.M.Co Crispi, Ministerio de Salud de la Provincia de Santa Fe, Argentina https://orcid.org/0000-0003-0871-7017
  • Pablo Martino PhD en Psicología. Consejo Nacional de Investigaciones Científicas y Técnicas (CONICET), Argentina. Universidad Nacional de Rosario, Argentina. https://orcid.org/0000-0002-5633-2050
  • Cristian F. Vera Médico Psiquiatra. Universidad Nacional de Rosario, Argentina.
  • José Bonet Médico Psiquiatra. Centro Estrés de la Fundación Favaloro. Director de la Maestría en Psicoinmunoneuroendocrinología, Universidad Favaloro, Argentina

DOI:

https://doi.org/10.53680/vertex.v34i161.483

Keywords:

Schizophrenia, Niacin (nicotinic acid), Oral use, Topical use, Skin rush

Abstract

Introduction: Although there is an abnormal presentation of Niacin Response Syndrome (ANRS) in schizophrenic patients (SZ) compared to subjects with other psychiatric illnesses and with healthy individuals. However, most of the literature is based on studies that have used tests of niacin topical administration, observing, on the other hand, less scientific production of its oral administration. The objective was to determine the sensitivity of the oral niacin test as a method of detecting ASRN in EZ. Methods: A non-randomized clinical trial was carried out. Two groups were formed, the experimental or SZ, with 21 patients diagnosed with schizophrenia according to DSM-IV-TR SZ or schizoaffective disorder, and the HC group, made up of 20 healthy controls. Both groups were exposed to an oral niacin test and clinical-semiological tools were applied to evaluate the NRS. Results: 90.5% of the SZ group presented ANRS. In contrast, no participant in the HC group presented ANRS (0%). Conclusions: Oral niacin administration was sensitive to  the detection of ASRN in schizophrenia. Likewise, ASRN could be a gradual phenomenon and its prevalence could be dose-dependent, being lower the lower the dose of oral niacin used. Further trials with larger and randomized samples will be needed.

Downloads

Download data is not yet available.

Published

2023-10-10

How to Cite

Carena, F., Martino, P., Vera, C. F., & Bonet, J. (2023). Test for abnormal niacin response syndrome in schizophrenia: reclaiming the oral route. Vertex Revista Argentina De Psiquiatría, 34(161, jul.-sept.), 24–31. https://doi.org/10.53680/vertex.v34i161.483

Issue

Section

Artículos